FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2921593132> ?p ?o ?g. }

• W2921593132 endingPage "1713" @default.
• W2921593132 startingPage "1680" @default.
• W2921593132 abstract "Background & AimsCrohn’s disease (CD) is a lifelong illness with substantial morbidity, although new therapies and treatment paradigms have been developed. We provide guidance for treatment of ambulatory patients with mild to severe active luminal CD.MethodsWe performed a systematic review to identify published studies of the management of CD. The quality of evidence and strength of recommendations were rated according to the Grading of Recommendation Assessment, Development and Evaluation (GRADE) approach. Statements were developed through an iterative online platform and then finalized and voted on by a group of specialists.ResultsThe consensus includes 41 statements focused on 6 main drug classes: antibiotics, 5-aminosalicylate, corticosteroids, immunosuppressants, biologic therapies, and other therapies. The group suggested against the use of antibiotics or 5-aminosalicylate as induction or maintenance therapies. Corticosteroid therapies (including budesonide) can be used as induction, but not maintenance therapies. Among immunosuppressants, thiopurines should not be used for induction, but can be used for maintenance therapy for selected low-risk patients. Parenteral methotrexate was proposed for induction and maintenance therapy in patients with corticosteroid-dependent CD. Biologic agents, including tumor necrosis factor antagonists, vedolizumab, and ustekinumab, were recommended for patients failed by conventional induction therapies and as maintenance therapy. The consensus group was unable to clearly define the role of concomitant immunosuppressant therapies in initiation of treatment with a biologic agent.ConclusionsOptimal management of CD requires careful patient assessment, acknowledgement of patient preferences, evidence-based use of existing therapies, and thorough assessment to define treatment success. Crohn’s disease (CD) is a lifelong illness with substantial morbidity, although new therapies and treatment paradigms have been developed. We provide guidance for treatment of ambulatory patients with mild to severe active luminal CD. We performed a systematic review to identify published studies of the management of CD. The quality of evidence and strength of recommendations were rated according to the Grading of Recommendation Assessment, Development and Evaluation (GRADE) approach. Statements were developed through an iterative online platform and then finalized and voted on by a group of specialists. The consensus includes 41 statements focused on 6 main drug classes: antibiotics, 5-aminosalicylate, corticosteroids, immunosuppressants, biologic therapies, and other therapies. The group suggested against the use of antibiotics or 5-aminosalicylate as induction or maintenance therapies. Corticosteroid therapies (including budesonide) can be used as induction, but not maintenance therapies. Among immunosuppressants, thiopurines should not be used for induction, but can be used for maintenance therapy for selected low-risk patients. Parenteral methotrexate was proposed for induction and maintenance therapy in patients with corticosteroid-dependent CD. Biologic agents, including tumor necrosis factor antagonists, vedolizumab, and ustekinumab, were recommended for patients failed by conventional induction therapies and as maintenance therapy. The consensus group was unable to clearly define the role of concomitant immunosuppressant therapies in initiation of treatment with a biologic agent. Optimal management of CD requires careful patient assessment, acknowledgement of patient preferences, evidence-based use of existing therapies, and thorough assessment to define treatment success." @default.
• W2921593132 created "2019-03-22" @default.
• W2921593132 creator A5008149243 @default.
• W2921593132 creator A5017585326 @default.
• W2921593132 creator A5018632668 @default.
• W2921593132 creator A5019662862 @default.
• W2921593132 creator A5019773888 @default.
• W2921593132 creator A5020295675 @default.
• W2921593132 creator A5020750865 @default.
• W2921593132 creator A5022687921 @default.
• W2921593132 creator A5028386079 @default.
• W2921593132 creator A5028728330 @default.
• W2921593132 creator A5036406384 @default.
• W2921593132 creator A5046814722 @default.
• W2921593132 creator A5051370494 @default.
• W2921593132 creator A5055359298 @default.
• W2921593132 creator A5055638169 @default.
• W2921593132 creator A5056355381 @default.
• W2921593132 creator A5059484368 @default.
• W2921593132 creator A5062818239 @default.
• W2921593132 creator A5063210073 @default.
• W2921593132 creator A5076996656 @default.
• W2921593132 creator A5078207979 @default.
• W2921593132 creator A5078621310 @default.
• W2921593132 creator A5083616352 @default.
• W2921593132 creator A5087430474 @default.
• W2921593132 date "2019-08-01" @default.
• W2921593132 modified "2023-10-02" @default.
• W2921593132 title "Canadian Association of Gastroenterology Clinical Practice Guideline for the Management of Luminal Crohn’s Disease" @default.
• W2921593132 cites W1594183633 @default.
• W2921593132 cites W1761355724 @default.
• W2921593132 cites W1803773569 @default.
• W2921593132 cites W1829867743 @default.
• W2921593132 cites W1911418949 @default.
• W2921593132 cites W1940516511 @default.
• W2921593132 cites W1964225748 @default.
• W2921593132 cites W1968616184 @default.
• W2921593132 cites W1973289259 @default.
• W2921593132 cites W1973435440 @default.
• W2921593132 cites W1976676963 @default.
• W2921593132 cites W1980692490 @default.
• W2921593132 cites W1981815056 @default.
• W2921593132 cites W1986036750 @default.
• W2921593132 cites W1988033668 @default.
• W2921593132 cites W1988572906 @default.
• W2921593132 cites W1989167852 @default.
• W2921593132 cites W1990311132 @default.
• W2921593132 cites W1991810959 @default.
• W2921593132 cites W1995864039 @default.
• W2921593132 cites W1997402233 @default.
• W2921593132 cites W2000368489 @default.
• W2921593132 cites W2000500639 @default.
• W2921593132 cites W2003314961 @default.
• W2921593132 cites W2006396734 @default.
• W2921593132 cites W2008365376 @default.
• W2921593132 cites W2008497900 @default.
• W2921593132 cites W2008551220 @default.
• W2921593132 cites W2008719667 @default.
• W2921593132 cites W2009025779 @default.
• W2921593132 cites W2011135579 @default.
• W2921593132 cites W2011657924 @default.
• W2921593132 cites W2011837830 @default.
• W2921593132 cites W2012440800 @default.
• W2921593132 cites W2013592287 @default.
• W2921593132 cites W2014352723 @default.
• W2921593132 cites W2015161836 @default.
• W2921593132 cites W2019150265 @default.
• W2921593132 cites W2020350753 @default.
• W2921593132 cites W2021015942 @default.
• W2921593132 cites W2021642055 @default.
• W2921593132 cites W2022661087 @default.
• W2921593132 cites W2030158949 @default.
• W2921593132 cites W2030638161 @default.
• W2921593132 cites W2031139877 @default.
• W2921593132 cites W2043211155 @default.
• W2921593132 cites W2043953510 @default.
• W2921593132 cites W2048729604 @default.
• W2921593132 cites W2050445965 @default.
• W2921593132 cites W2055266605 @default.
• W2921593132 cites W2055399737 @default.
• W2921593132 cites W2055879151 @default.
• W2921593132 cites W2056917411 @default.
• W2921593132 cites W2058855372 @default.
• W2921593132 cites W2059019883 @default.
• W2921593132 cites W2059390106 @default.
• W2921593132 cites W2059428047 @default.
• W2921593132 cites W2064862615 @default.
• W2921593132 cites W2069009549 @default.
• W2921593132 cites W2071358889 @default.
• W2921593132 cites W2075090387 @default.
• W2921593132 cites W2077531651 @default.
• W2921593132 cites W2084472999 @default.
• W2921593132 cites W2085127303 @default.
• W2921593132 cites W2088513474 @default.
• W2921593132 cites W2089953373 @default.
• W2921593132 cites W2090740742 @default.
• W2921593132 cites W2093770528 @default.
• W2921593132 cites W2094017943 @default.

• next